Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
Autor: | Howard L. Weiner, Ludwig Kappos, Martin Merschhemke, Catherine Lubetzki, David G. MacManus, David Miller, Fred D. Lublin, Bruce A.C. Cree, Hans-Peter Hartung, Tarek A. Yousry, Bernard M. J. Uitdehaag, Norman Putzki, Xavier Montalban, Claudia A. M. Wheeler-Kingshott, Dieter A. Häring, Bingbing Li, Özgür Yaldizli, Maria Pia Sormani, Jerry S. Wolinsky, Mark S. Freedman |
---|---|
Přispěvatelé: | Neurology, Amsterdam Neuroscience - Neuroinfection & -inflammation |
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
Clinical Sciences Lesion volume Primary Progressive Multiple Sclerosis Placebo group Lesion 03 medical and health sciences 0302 clinical medicine Atrophy Internal medicine medicine 030212 general & internal medicine Research Articles business.industry General Neuroscience Hazard ratio Neurosciences medicine.disease Brain size Cardiology T2 lesions Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery Research Article |
Zdroj: | Annals of clinical and translational neurology, vol 5, iss 3 Miller, D H, Lublin, F D, Sormani, M P, Kappos, L, Yaldizli, Ö, Freedman, M S, Cree, B A C, Weiner, H L, Lubetzki, C, Hartung, H-P, Montalban, X, Uitdehaag, B M J, MacManus, D G, Yousry, T A, Gandini Wheeler-Kingshott, C A M, Li, B, Putzki, N, Merschhemke, M, Häring, D A & Wolinsky, J S 2018, ' Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study ', Annals of Clinical and Translational Neurology, vol. 5, no. 3, pp. 346-356 . https://doi.org/10.1002/acn3.534 Annals of Clinical and Translational Neurology Annals of Clinical and Translational Neurology, 5(3), 346-356. John Wiley and Sons Ltd |
ISSN: | 0073-1692 2328-9503 |
Popis: | Author(s): Miller, David H; Lublin, Fred D; Sormani, Maria Pia; Kappos, Ludwig; Yaldizli, Ozgur; Freedman, Mark S; Cree, Bruce AC; Weiner, Howard L; Lubetzki, Catherine; Hartung, Hans-Peter; Montalban, Xavier; Uitdehaag, Bernard MJ; MacManus, David G; Yousry, Tarek A; Gandini Wheeler-Kingshott, Claudia AM; Li, Bingbing; Putzki, Norman; Merschhemke, Martin; Haring, Dieter A; Wolinsky, Jerry S | Abstract: ObjectiveTo investigate the relationship between brain volume and disability worsening over ≥3nyears in the natural history of primary progressive multiple sclerosis using data from the placebo group of the INFORMS trial (nn=n487; clinicaltrials.gov NCT00731692).MethodsMagnetic resonance imaging scans were collected annually. Brain volume loss was determined using SIENA. Patients were stratified by baseline normalized brain volume after adjusting for demographic and disease-burden covariates.ResultsBaseline normalized brain volume was predictive of disability worsening: Risk of 3-month confirmed disability progression was reduced by 36% for high versus low baseline normalized brain volume (Cox's model hazard ratio 0.64, Pn=n0.0339; log-rank test: Pn=n0.0297). Moreover, on-study brain volume loss was significantly associated with disability worsening (Pn=n0.012) and was evident in patients with or without new lesions or relapses. Brain volume loss depended significantly on baseline T2 lesion volume (Pnln0.0001). Despite low inflammatory activity at baseline (13% of patients had gadolinium-enhancing lesions) and throughout the study (mean 0.5 new/enlarging T2 lesions and 172nmm3 T2 lesion volume increase per year), baseline T2 lesion volume was substantial (mean 10ncm3). Lower normalized brain volume at baseline correlated with higher baseline T2 volume and older age (both Pnln0.0001).InterpretationBaseline brain volume and the rate of ongoing brain atrophy are significantly associated with disability worsening in primary progressive multiple sclerosis. Brain volume loss is significantly related to baseline T2 lesion volume, but partially independent of new lesion activity, which might explain the limited efficacy of anti-inflammatory treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |